Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31667435 | 0.85 | MIF (0.53) | MIFNPC1METALDH1A1KMT2A | |
| SCHEMBL637196 | 0.72 | NPC1 (0.42) | NPC1ALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL18189848 | 0.71 | NPC1 (0.52) | MIFNPC1METALDH1A1KMT2A | |
| SCHEMBL14800038 | 0.71 | MIF (0.44) | MIFNPC1ALDH1A1KMT2AMAPT | |
| SCHEMBL19857729 | 0.70 | TSHR (0.44) | NPC1KMT2AMEN1KDM4E | |
| SCHEMBL29925168 | 0.69 | HTR2C (0.48) | NPC1MAPT | |
| SCHEMBL28840671 | 0.69 | HTR2C (0.48) | NPC1MAPT | |
| SCHEMBL31667365 | 0.69 | KCNH2 (0.39) | NPC1ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL32686754 | 0.69 | NPC1 (0.43) | MIFNPC1METALDH1A1 | |
| SCHEMBL32686737 | 0.69 | NPC1 (0.40) | MIFNPC1METALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | MIF 4403/4885NPC1 200/4885MET 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.